Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.50 |
| ▸ | SRC | P12931 | 5/20 | 0.50 |
| ▸ | GSK3B | P49841 | 5/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267534 | 0.87 | AURKA (0.46) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL801846 | 0.81 | AURKA (0.76) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL801504 | 0.78 | AURKA (0.50) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802423 | 0.73 | AURKA (0.71) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL13055018 | 0.73 | AURKA (0.37) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL12653509 | 0.72 | AURKA (0.54) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802519 | 0.70 | AURKA (0.74) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802435 | 0.70 | AURKA (0.82) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802012 | 0.70 | AURKA (0.72) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802029 | 0.70 | AURKA (0.72) | AURKAAURKBSRCGSK3BEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7390815-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | AURKA 8/4885AURKB 19/4885SRC 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.